Ind-Swift Laboratories Ltd

Ind-Swift Laboratories has faced significant volatility, reaching a new 52-week low of Rs. 85.6, with a cumulative drop of 18.24% over four days. The stock is trading below all major moving averages and has declined 12.37% over the past year, contrasting with the Sensex's gains.

Ind-Swift Laboratories has experienced a revision in its score, reflecting ongoing challenges in the market. The stock recently reached a 52-week low and has been underperforming compared to sector benchmarks. Despite these difficulties, the company maintains a robust product portfolio and distribution network, indicating potential for future recovery. Ind-Swift Laboratories, a microcap pharmaceutical firm, has faced significant headwinds, including a recent drop in stock price and a bearish trend across multiple moving averages. The stock's volatility and negative returns over the past year have prompted a revision in its evaluation by MarketsMOJO. Investors are advised to remain vigilant and consider broader market conditions and company fundamentals when assessing their positions.

Ind-Swift Laboratories, a microcap pharmaceutical company, has reported a negative performance in the quarter ending September 2024. The company's profit after tax, net sales, and operating profit have all seen significant declines year on year. Non-operating income is high, and the earnings per share have also decreased. MarketsMOJO has given a 'Strong Sell' call for the company's stock.

The stock has been given a 'Sell' call by MarketsMOJO due to its negative trend in the near term. Ind-Swift Laboratories, a microcap pharmaceutical company, has reported a negative performance in the quarter ending June 2024, with a decline in net sales, profit before tax, and profit after tax. The company's operating profit margin and earnings per share have also decreased, leading to a 'Sell' call by MarketsMOJO.

Ind-Swift Laboratories, a smallcap pharmaceutical company, saw a 7.53% increase in its stock price on August 7th, 2024, in line with the pharma sector's 2.25% gain. The stock has been consistently trading above its moving averages and is close to its 52 week high, indicating a positive trend. MarketsMOJO has given a 'Hold' call for the stock.

Ind-Swift Laboratories, a smallcap pharmaceutical company, experienced a 7.01% rise in stock price on August 2nd, 2024. This was driven by the company's strong market performance, surpassing its sector by 4.39%. The stock also reached a new 52-week high of Rs.181.55. According to MarketsMOJO, the current call for Ind-Swift Laboratories' stock is 'Hold', based on its performance and market trends, without any influence from investors or experts. The company's stock is trading higher than its moving averages, indicating a positive trend. Compared to the overall market, Ind-Swift Laboratories has shown a strong 1-day and 1-month performance.

Ind-Swift Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on August 2nd, 2024. With a 'Hold' rating from MarketsMOJO, the stock is currently trading higher than its moving averages and has outperformed the sector in today's trading session. In the past year, the stock has shown a remarkable 92.28% increase, indicating strong performance and potential for future growth.

Ind-Swift Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on August 1st, 2024. Despite being rated as 'Hold' by MarketsMOJO, the stock is still performing well and has shown a strong performance in the past year, indicating a positive trend for the company and its investors.

Ind-Swift Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 31st, 2024. The stock has outperformed the sector by 12.01% and is currently trading higher than its moving averages. With a strong performance in the past year, Ind-Swift Laboratories shows potential for growth in the pharmaceutical industry.

Ind-Swift Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 30th, 2024. The stock has outperformed its sector by 4.81% and gained 17.28% in the last 6 days. With a 'Hold' recommendation from MarketsMOJO, the company has consistently performed well and has shown a strong potential for growth.

Ind-Swift Laboratories, a microcap pharmaceutical company, has been gaining attention in the stock market with its recent 52-week high on July 29, 2024. According to MarketsMOJO, the stock has been given a 'Hold' call and is currently trading at Rs 147.1, only 0.72% away from its high. The stock has consistently outperformed the sector and market, making it a strong performer in the industry.

Ind-Swift Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 15, 2024. The stock has been performing well, outperforming the sector by 4.96% and showing a consecutive gain for the past 3 days. It is currently trading above its moving averages, indicating a positive trend and potential for further growth.

Ind-Swift Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 9th, 2024. The stock has been given a 'Hold' rating by MarketsMOJO and has consistently outperformed the sector and its moving averages. With a remarkable growth of 52.49% in the past year, the company shows potential in the market.

Ind-Swift Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 1st, 2024. The stock has outperformed the sector by 4.58% and has been on a consecutive gain for the past 6 days, resulting in a 17% increase in returns. It is also trading higher than its moving averages, indicating a positive trend. With a significant growth of 59.63% in the past year, the company shows strong potential in the pharmaceutical industry.

Ind-Swift Laboratories, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO on June 24, 2024. The stock has shown a bullish trend with a 1.07% return since June 20, 2024. However, the company's long-term fundamentals are weak, with operating losses and low ability to service debt. 48.57% of promoter shares are pledged, which may impact stock prices in falling markets.

Ind-Swift Laboratories, a microcap pharmaceutical company, has been downgraded to a 'Sell' by MarketsMOJO due to operating losses, slow sales growth, high debt to EBITDA ratio, and declining financial performance. Despite some bullish technical indicators and attractive valuation, investors should be cautious of the company's weak fundamentals.

Ind-Swift Laboratories, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its improved technical trend. Despite a 61.27% return in the last year, the company's profits have fallen by -19.5%. With weak long-term fundamentals and high promoter pledged shares, it is currently trading at a discount and should be monitored before making any investment decisions.

Ind-Swift Laboratories, a microcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO due to weak long-term fundamentals. The company has an average ROCE of 0% and low ability to service debt. Recent financial performance has also been flat, with profits falling by -29.4%. While the stock has outperformed the market in the past year, its high promoter pledged shares and potential overvaluation suggest caution for investors.

Ind-Swift Laboratories, a microcap pharmaceutical company, has been on a winning streak in the market, outperforming its sector by 0.63%. With a remarkable 36.65% increase in its stock price in the past 8 days, the company has also been recommended as 'Hold' by MarketsMOJO. Its impressive performance of 108.87% in the past year shows its potential for growth.